Loading
The study in which brentuximab vedotin made relapsed systemic anaplastic large cell lymphoma shrink in 86 per cent of patients and disappear on scans in 57 per cent.
A multicentre phase 2 trial of brentuximab vedotin 1.8 mg/kg intravenously every three weeks over 30 minutes, as an outpatient infusion, in patients with systemic anaplastic large cell lymphoma recurring after at least one prior therapy. The primary endpoint was overall objective response by independent central review.
The evidence behind the statement on both ALCL pages that brentuximab vedotin is highly active at relapse, and the step that led to ECHELON-2 and first-line use.
Shares Brentuximab vedotin phase 2 in relapsed systemic anaplastic large cell lymphoma (SG035-0004), ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, CD30, Brentuximab vedotin.
Shares Brentuximab vedotin phase 2 in relapsed systemic anaplastic large cell lymphoma (SG035-0004), ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, CD30, Brentuximab vedotin.
Shares ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Brentuximab vedotin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/